ENCLOSED HEREWITH BOARD MEETING OUTCOME DATED 13/02/2026
Awaiting price reaction for this filing.
Nutricircle Limited's board, meeting on 13 February 2026, approved the unaudited financial results for Q3 and nine months ended 31 December 2025, along with the limited review report from NSVR & Associates (clean, unqualified). Revenue from operations jumped sharply to ₹554.02 lakh in Q3 FY26 versus ₹145.92 lakh in Q3 FY25, and to ₹1,288.29 lakh for 9M FY26 versus ₹145.92 lakh in 9M FY25. Profit after tax swung from a loss of ₹66.13 lakh in 9M FY25 to a profit of ₹27.46 lakh in 9M FY26, with Q3 FY26 PAT at ₹17.92 lakh. The board also approved conversion of 11,00,000 warrants into equity shares (₹10 face value, ₹10 issue price) allotted to promoter and Managing Director Mr. Hitesh Mohanlal Patel, with the balance 75% subscription of ₹82.50 lakh received and confirmed by the statutory auditor. An earlier tranche of 97,28,220 equity shares (₹9.73 crore) had already been allotted on 5 December 2024 under the same preferential approval. Reserves remain in the negative at ₹(420.19) lakh as of 31 March 2025.
Strong topline recovery and a return to profit are positive signals, but the sharp revenue jump warrants closer scrutiny as prior-year base was very small. The promoter-led preferential allotment (related-party transaction) will increase the promoter's stake and dilute non-promoter shareholders slightly, though pricing at face value limits dilution cost.